ipilimumab based treatment | ipilimumab alone | ipilimumab based treatment | anti-CTLA-4 | atezolizumab based treatment | nivolumab based treatment | anti-PD-(L)1 | pembrolizumab based treatment | pembrolizumab alone | pembrolizumab based treatment | Immune checkpoint association | ||||||
ipilimumab alone | Ipilimumab (10 mg/kg) | ipilimumab plus gp100 | ipilimumab plus SoC | tremelimumab | atezolizumab plus cometinib | atezolizumab plus SoC | nivolumab alone | nivolumab followed by ipilimumab | pembrolizumab alone | pembrolizumab (10mg/kg) | pembrolizumab (10mg/kg) 2 weeks | pembrolizumab (2mg/kg) | pembrolizumab plus SoC | nivolumab plus ipilimumab | relatlimab plus nivolumab |